In recent years, the company has expanded its pharmaceutical R&D CXO presence to Heze, Shandong, and Shijiazhuang, Hebei, leading to the establishment of Shandong RuZhi Biopharm and Shijiazhuang Discovery. These subsidiaries aim to deliver closer, high-quality services to clients while forming a synergistic and complementary relationship with the Nanjing headquarters. Notably, the establishment of the Traditional Chinese Medicine Research Institute, the Improved Innovation Research Institute, and the Peptide Research Institute strengthens the company’s growth in critical and emerging areas of the CRO field.

Additionally, the company serves as a professional CMO/CDMO base, featuring nearly 10 diverse production lines, including:

The company boasts over 160 advanced scientific instruments, including HPLC and LC-MS equipment from Agilent, Shimadzu, and Thermo Fisher, supporting research across APIs, peptides, tablets, injectables, topical formulations, inhalation products, and ophthalmic drugs. With full-chain drug development capabilities encompassing preclinical PCC, API, formulation CMC, and clinical services, the company is well-positioned to meet diverse R&D demands.